Core Insights - VivoSim Labs, Inc. is presenting new data on its NAMkind™ liver and intestine models at the Society of Toxicology meeting, demonstrating their ability to predict toxicity and side effects of antibody drug conjugates (ADCs) [1][4] Group 1: Company Overview - VivoSim Labs, Inc. specializes in next-generation New Approach Methodologies (NAMs) for preclinical safety, focusing on testing drugs in 3D human tissue models of the liver and intestine [7] - The company operates from San Diego, CA, and is expanding its services globally, including in the US, Europe, Korea, and China [6][7] Group 2: Product and Technology - The NAMkind™ models can provide insights into target engagement, premature linker cleavage, and bystander effects in complex human cell models [3] - Testing of approved ADC therapies in NAMkind™ models has shown a close correlation with clinical results, particularly regarding liver toxicity and intestinal side effects [4][5] Group 3: Market Potential and Demand - With hundreds of ADCs in development globally, the NAMkind™ models are positioned as a powerful tool to mitigate off-target toxicity and enhance drug candidate selection [2] - The FDA's announcement to refine animal testing requirements in favor of NAM methods is expected to accelerate the adoption of these human tissue models [7]

Core Insights - VivoSim Labs has appointed JCBio for Korea and Tekon Biotech for China to distribute its NAMKind™ toxicology services, enhancing its commercial presence in the Asia-Pacific region [1][12] - The demand for human-relevant toxicology is increasing as drug developers seek faster and more reliable preclinical safety assessments [2][11] Distribution Agreements - JCBio will facilitate the deployment of NAMKind™ services in Korea, providing local coordination and scientific engagement to streamline evaluations [9][8] - Tekon Biotech aims to introduce VivoSim's NAMKind™ platforms to the Greater China market, addressing the need for accurate preclinical safety data [4][5] Market Dynamics - The in-vitro toxicology testing market in China is projected to grow from approximately $1.05 billion in 2023 to $2.26 billion by 2030, driven by increased R&D investment and evolving regulatory standards [5] - The pharmaceutical industry in China is shifting from generic manufacturing to innovative drug development, increasing the demand for predictive tools to mitigate late-stage clinical failures [7] Regulatory Alignment - Korea's regulatory body, MFDS, is aligning with the U.S. FDA's momentum towards adopting NAM-based evidence, which is expected to accelerate the acceptance of new toxicology techniques [3] Technological Advantages - VivoSim's NAMKind™ platform offers a modern approach to toxicology, designed to save time, reduce risk, and cut costs by providing human-based screening insights [10][12] - The platform is capable of delivering actionable results with a targeted 30-day turnaround time per compound, making it practical for both small and large molecules [12]

Core Insights - VivoSim Labs, Inc. has appointed Dr. Amar Sethi as Chief Scientific Officer to enhance its scientific strategy and capabilities in drug testing and toxicology [1][5] Company Overview - VivoSim Labs is a pharmaceutical and biotechnology services company focused on testing drugs in three-dimensional human tissue models, specifically for liver and intestine [6] - The company anticipates increased adoption of its human tissue models following FDA's announcement to refine animal testing requirements in favor of non-animal methods [6] Leadership Appointment - Dr. Amar Sethi brings three decades of experience in pharmaceutical drug development, CRO leadership, and diagnostic innovation [2] - His previous roles include leading global clinical programs and developing FDA-qualified biomarker platforms, contributing to significant business growth [4] Strategic Focus - Dr. Sethi will lead initiatives in toxicology, translational models, and bioanalytics, aiming to enhance multi-parametric toxicity prediction using human-relevant systems [3] - The company aims to integrate advanced 3D biology with AI-driven analytics to provide earlier decision-ready insights for sponsors [5] Market Positioning - VivoSim Labs is positioned to be a preferred scientific partner as the industry increasingly adopts 3D NAM systems for drug development [5]

Core Points - Charles River Laboratories announced the resignation of CFO Flavia H. Pease, effective September 29, 2025, and appointed Michael G. Knell as interim CFO while a search for a permanent successor is conducted [1][2] - The company reaffirmed its financial guidance for 2025, including revenue and non-GAAP earnings per share, based on its current outlook for third-quarter performance [3] Management Transition - Flavia H. Pease contributed significantly during her three years at the company, helping to navigate challenging demand environments and optimize cost structures [2] - Michael G. Knell, who has been with the company since 2017, is expected to lead the finance organization effectively during the interim period [2] Financial Guidance - The company maintains its previously provided financial guidance for 2025, indicating confidence in its revenue and earnings projections [3]

Core Insights - VivoSim Labs has appointed Tony Lialin as Chief Commercial Officer to enhance its AI-enabled NAMkind™ liver and intestine toxicology services in a growing market [1][2] - The global market for liver and gastrointestinal in-vitro models and toxicology services generated $641 million in revenue in 2024, with services accounting for 53.1% of this revenue [3] - The U.S. market for liver toxicology models and services is valued at $325 million, representing 50.8% of the global market [3] Market Opportunity - The global in vitro liver model market is experiencing a growth rate of 5.9% CAGR from 2020 to 2024, indicating increasing adoption of 3D human-relevant systems [3] - Regulatory changes, such as the FDA Modernization Act 2.0, are driving the adoption of non-animal methodologies, which supports the use of human-relevant in vitro models for ADME and toxicology [4] Technology and Services - VivoSim Labs utilizes AI to enhance the analysis of multi-parametric toxicity signatures in liver and intestinal organoid assays, improving the reliability of dose-response analyses [5] - The company's NAMkind™ models are designed to provide critical toxicology insights earlier in the drug development process, aiming to streamline pre-IND decision-making [6] Company Overview - VivoSim Labs focuses on testing drugs and drug candidates using 3D human tissue models of the liver and intestine, offering insights through its NAM models [7] - The company anticipates increased adoption of its human tissue models following recent FDA announcements aimed at refining animal testing requirements [7]